Skip NavigationSkip to Content

Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines

  1. Author:
    Polacino, P.
    Stallard, V.
    Montefiori, D. C.
    Brown, C. R.
    Richardson, B. A.
    Morton, W. R.
    Benveniste, R. E.
    Hu, S. L.
  2. Author Address

    Hu SL Univ Washington, Dept Pharmaceut Box 357331 Seattle, WA 98195 USA Univ Washington, Reg Primate Res Ctr Seattle, WA 98195 USA Univ Washington, Dept Biostat Seattle, WA 98195 USA Bristol Myers Squibb Pharmaceut Res Inst Seattle, WA 98121 USA Duke Univ, Med Ctr Durham, NC USA NCI Frederick, MD 21701 USA Henry M Jackson Fdn Rockville, MD USA
    1. Year: 1999
  1. Journal: Journal of Virology
    1. 73
    2. 4
    3. Pages: 3134-3146
  2. Type of Article: Article
  1. Abstract:

    We previously reported that immunization with recombinant simian immunodeficiency virus SIVmne envelope (gp160) vaccines protected macaques against intravenous challenge by the cloned homologous virus E11S but that this protection was only partially effective against the uncloned virus, SIVmne. In the present study, we examine the protective efficacy of this immunization regimen against infection by a mucosal route. We found that the same gp160-based vaccines were highly effective against intrarectal infection not only with the E11S clone but also with the uncloned SIVmne, Protection against mucosal infection is therefore achievable by parenteral immunization with recombinant envelope vaccines. Protection appears to correlate with high levels of SIV-specific antibodies and, in animals protected against the uncloned virus, the presence of serum-neutralizing activities, To understand the basis for the differential efficacies against the uncloned virus by the intravenous versus the intrarectal routes, me examined viral sequences recovered from the peripheral blood mononuclear cells of animals early after infection by both routes. We previously showed that the majority (85%) of the uncloned SIVmne challenge stock contained V1 sequences homologous to the molecular clone from which the vaccines were made (E11S type), with the remainder (15%) containing multiple conserved changes (the variant types). In contrast to intravenously infected animals, from which either E11S-type or the variant type V1 sequences could be recovered in significant proportions, animals infected intrarectally had predominantly E11S-type sequences. Preferential transmission or amplification of the E11S-type viruses may therefore account in part for the enhanced efficacy of the recombinant gp160 vaccines against the uncloned virus challenge by the intrarectal route compared with the intravenous route. [References: 50]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel